About Atlas Biotech

Our team is driven by the idea that curative treatments for many devastating diseases are within reach. We just need the right tools and data to get us there.

The founding team spun Atlas Biotech’s mutational scanning technology out of Penn State in 2024, and we’ve been adding team members who share our excitement for science and solving challenging problems.

Meet the Team Revolutionizing Genomics

Our Leadership

  • Josh Reynolds, PhD

    FOUNDER & CEO

    Josh is the founder and CEO of Atlas Biotech. He leads the team and drives outcomes across the organization. Dr. Reynolds trained in evolution, drug resistance and structural oncology under Drs. Justin Pritchard and Nikolay Dokholyan at the Pennsylvania State University.

    LinkedIn→
    Publications →

  • Marta Tomaszkiewicz, PhD

    CO-FOUNDER & HEAD OF GENOMICS

    Marta is the Head of Genomics at Atlas Biotech. Marta received her doctorate from École normale supérieure de Lyon and has over a decade of experience in genomics and next generation sequencing. She applies that expertise to the functional genomics tools being developed and deployed at Atlas.

    LinkedIn→
    Publications →

  • Simon Beardsley, MS

    SENIOR RESEARCH SCIENTIST

    Simon Beardsley is a Senior Research Scientist at Atlas Biotech specializing in cell culture processes and assays. He leads cell library generation, screening pipelines, and team operations supporting functional genomics in oncology drug-resistance research.


    LinkedIn→
    Publications →

  • Brianna Hnath, PhD

    SENIOR SCIENTIST

    Brianna is a Senior Scientist at Atlas Biotech with expertise in neuroscience and biomedical engineering. Her PhD research focused on protein engineering, aggregation kinetics, and neurodegenerative disease pathology, particularly ALS.


    LinkedIn→
    Publications→

Our Staff

  • Daniel Doucek

    RESEARCH TECHNICIAN

  • Cristal Alonso

    RESEARCH TECHNICIAN

  • Patty Hennessey

    CO-OP INTERN (PSU)

Our focus

Our work has historically been centered in oncology, but we are developing applications for our technologies in rare diseases, inflammatory disease models, and more.

With the demand for data at an all-time high, we aim to be a key provider of high quality datasets including massively multiplexed genotype-phenotype measurements, genome-wide screens, and other sources of big data.

Our future

We specialize in functional genomics and other synthetic biology techniques, which provide deeper insights into structure-function relationships that drive biology and disease.

Designing and screening libraries is our bread and butter, but we’re also interested in developing novel assays that answer niche or specifically challenging questions.

Next up:

Publications

Explore